ClinicalTrials.gg
RecruitingNCT06489483Updated Dec 12, 2025

Action Regulation Behavioral

An interventional study of Action Regulation Movement Task in Parkinson Disease, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Parkinson Disease by University of Texas Southwestern Medical Center — 5 open to participants now, 5 under way, none of them phase 3. Parkinson Disease · University of Texas Southwestern Medical Center.

Started
2024
the only one that year
No phase
8 of 13
4 open now
Registered
11th of 13
by date

Among the 13 studies in Parkinson Disease by University of Texas Southwestern Medical Center, this one is the only one that started in 2024, is one of 8 with no phase, and was the 11th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 13 studies in Parkinson Disease by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Parkinson Disease by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is a neurodegenerative disorder involving a part of the brain that is responsible for motor control, which not only results in changes or disruptions in movement, but also cognitive dysfunctions. Given that the decline of muscle control such as tremors, with difficulty walking or the ability to switch tasks once in movement, greatly affects the quality of daily life. Action regulation is a critical executive function (cognitive control over behavior), which includes actions such as suppressing activity when selecting between options, making decisions about stopping unwanted or inappropriate actions, and switching to new actions in response to environmental changes. Parkinson's disease (PD) has been shown to disrupt action inhibition which can be considered a measure to the progression of PD.

The purpose of this research study is to better understand the mechanism of action regulations in PD patients and how action regulations in PD can be improved using dopaminergic treatment, which is a drug that either releases or involves dopamine, which is a neurotransmitter involved in sending signals to nerve cells.

You are asked to participate in this research study because you are receiving a dopaminergic medication for treatment of your Parkinson's disease. There is currently no theory that integrates the mechanisms of action regulation into a unified framework, which this study aims to address. The researchers hope to learn more about the mechanisms of action regulation in PD patients and to help decrease action regulation disruptions in PD patients. This study will help characterize the motor behavior of PD patients.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Levodopa medication
  • motor cortex
  • basal ganglia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

For Parkinson's Disease Patients:

Inclusion Criteria:

  • Diagnosis of Parkinson's Disease by a movement disorder neurologist
  • Levodopa responsive with clearly defined "on" periods, with at least 30% improvement in UPDRS III scores on vs off
  • Willingness and ability to complete the behavioral experiments for up 3.5 hours
  • No vision or hearing problems that impair ability to participate with the proposed tasks as assessed by the study investigators

Exclusion Criteria:

  • Patients with history of secondary Parkinsonism, stroke, or progressive central nervous system disease other than Parkinson's Disease
  • Patients with a disease or condition that prevents understanding or communication of , study demands, and testing protocol including cognitive decline, diagnosed forms of dementia, significant memory impairment (\<23), or hearing loss that prevents adequate communication with researcher

For Healthy subjects:

Inclusion Criteria:

  • No history any diagnosed neurological disease(s), including movement disorders or cognitive decline
  • No vision or hearing problems that impair ability to participate with the proposed tasks as assessed by the study investigators
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Parkinson's Disease Patients

    Patients that have been diagnosed with Parkinson's Disease and are responsive to levodopa medication. Patients will complete a behavioral task.

    Behavioral: Action Regulation Movement Task

  • Active comparator
    Healthy Controls

    Men and women between the ages of 18-80. Spouse of PD patient who participates in this study with no history of any diagnosed neurological disease(s), including movement disorders or cognitive decline. No vision or hearing problems that impair ability to participate with the proposed tasks as assessed by the study investigators.

    Behavioral: Action Regulation Movement Task

Interventions

  • BehavioralAction Regulation Movement Task

    A joystick is utilized to trace the movement of a visual stimulus on a computer screen. In stop signal task, the subjects are required to move a reference dot to reach to a target dot by controlling a joystick and stop their movements when the target turns red. During the switch task, subjects will be required to switch their joystick movement trajectory when the target location is switched to one of the other target locations.

06

What researchers measure

Primary outcomes

  1. Stop-Signal Task

    Each patient will complete a joystick-based stop-signal task which assesses reaction time, stop reaction time, accuracy, and joystick traces.

    Time frame: Baseline

  2. Switch Task

    Each patient will complete a joystick-based switch task which assess reaction time, switch reaction time, accuracy, and joystick traces.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Following data acquisition, de-identified data will be shared with research team at University of California, Riverside.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Nov 2026, 31 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 31 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 8, 2024
StartActual
Apr 24, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2027
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06489483
Collaborators
University of California, Riverside
Responsible party
Nader Pouratian (Professor and Chair of Neurological Surgery, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jul 8, 2024
Start date
Apr 24, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Dec 12, 2025

Study contacts

Nader Pouratian, MD, Phd
Contact
nader.pouratian@utsouthwestern.edu
(214) 645-5465
Sahil Chilukuri, BS
Contact
sahil.chilukuri@utsouthwestern.edu
(214) 645-5465

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion